Orphan-designated rare disease assets command this deal premium

Orphan drug designation transforms rare disease deal economics. Gene therapy deals for orphan indications reach $2.2B total value at Phase 2, while ERTs average $2.3B. The 7-year US market exclusivity, accelerated regulatory pathways, and $200K-$3.5M per-patient pricing create a unique commercial profile that drives premium licensing terms across all modalities.

Based on analysis of 600+ biopharma licensing deals from 2020-2026